41490-09-9

Usage

Uses

Used in Agricultural Industry:
3,5-Dichloro-4-propoxybenzoic acid is used as a herbicide for controlling broadleaf weeds and grasses in agricultural fields. It functions by inhibiting the enzyme protoporphyrinogen oxidase, which plays a crucial role in chlorophyll synthesis within plants. The disruption of this photosynthesis process results in the death of the targeted plants.
Used in Non-Crop Areas:
In non-crop areas, 3,5-Dichloro-4-propoxybenzoic acid is also utilized as a herbicide to manage unwanted plant growth. Its application helps in maintaining clear spaces and preventing the overgrowth of vegetation that could interfere with infrastructure or other non-agricultural activities.

InChI:InChI=1/C10H10Cl2O3/c1-2-3-15-9-7(11)4-6(10(13)14)5-8(9)12/h4-5H,2-3H2,1H3,(H,13,14)

Upstream product

• 1368285-65-7 methyl 3,5-dichloro-4-n-propoxybenzoate 

Downstream Products

• 1192829-45-0 5-{5-[3,5-dichloro-4-(propyloxy)phenyl]-1,2,4-oxadiazol-3-yl}isoquinoline 

Relevant academic research and scientific papers

Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist

A ligand-based virtual screening exercise examining likely bioactive conformations of AM 580 (2) and AGN 193836 (3) was used to identify the novel, less lipophilic RARα agonist 4-(3,5-dichloro-4-ethoxybenzamido)benzoic acid 5, which has good selectivity over the RARβ and RARγ receptors. Analysis of the medicinal chemistry parameters of the 3,5-substituents of derivatives of template 5 enabled us to design a class of drug-like molecules with lower intrinsic clearance and higher oral bioavailability which led to the novel RARα agonist 4-(3-chloro-4-ethoxy-5-isopropoxybenzamido)-2-methylbenzoic acid 56 that has high RARα potency and excellent selectivity versus RARβ (2 orders of magnitude) and RARγ (4 orders of magnitude) at both the human and mouse RAR receptors with improved drug-like properties. This RARα specific agonist 56 has high oral bioavailability (>80%) in both mice and dogs with a good PK profile and was shown to be inactive in cytotoxicity and genotoxicity screens.

ORGANIC COMPOUNDS

Novel benzofuran derivatives are disclosed. The derivatives have S1P1 receptor activity and/or disease modifying activity and find use in the treatment of conditions or diseases associated with the immune, vascular and nervous systems in animals and/or humans

S1P RECEPTORS MODULATORS

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.